Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COMPASS Pathways Plc CMPS

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary... see more

NDAQ:CMPS - Post Discussion

COMPASS Pathways Plc > David Nutt: Amanita Muscaria Due For More Research – The Dai
View:
Post by AwareInvestor on Mar 10, 2021 1:55pm

David Nutt: Amanita Muscaria Due For More Research – The Dai

Today host Cassandra Leah sits down with Dr David Nutt, a highly experienced neuropsychopharmacologist, the chair of the scientific advisory board for Compass Pathways, and a director of Psyched Wellness. David joins us this morning to discuss psychedelics and the science behind it, clinical research, and his take on Amanita Muscaria.
Be the first to comment on this post